title: Induction and regulation of casein kinase II during B lymphocyte activation.
abstract: This study evaluates the regulation of casein kinase II (CK II) activity in resting B cells induced to enter the cell cycle. The induction of B cell cycle progression PMA and ionomycin results in an oscillatory expression of CK II. This kinase activity is also elicited after direct physical interaction between B cells and activated, fixed Th cells, indicating that the increase seen in CK II activity is probably associated with the delivery of the competence-inducing signal to resting B cells. The selective inhibition of ornithine decarboxylase (ODC), the rate-limiting enzyme for polyamine biosynthesis, during PMA and ionomycin-induction of B cell cycle progression, inhibits the expression of CK II activity. The addition of polyamines to cytosolic preparations recovered from cells in which ODC is inhibited results in the appearance of CK II activity, showing that the ODC inhibitor does not directly inhibit the kinase. The treatment of B cells with cycloheximide results in the appearance of CK II activity within 15 min, and this induction is partially explainable by a cycloheximide-elicited increase in cellular levels of polyamines. The artificial elevation of cellular levels of cAMP simultaneous with the addition of PMA and ionomycin results in a 150 to 200% increase in detectable CK II levels, suggesting that the cAMP-dependent signaling cascade may participate during the early regulation of CK II. In contrast, the inhibition of protein kinase C does not adversely influence the early expression of CK II, while actually enhancing kinase activity by 18 h poststimulation.
authors.affiliation: Department of Microbiology and Immunology, University of Kentucky Medical Center, Lexington 40536-0084.
authors.forename: M
authors.initials: M
authors.lastname: DeBenedette
authors.forename: E C
authors.initials: EC
authors.lastname: Snow
mesh_terms: D000818:Animals; D001402:B-Lymphocytes / Q000502:physiology*; D003994:Bucladesine / Q000494:pharmacology; D002118:Calcium / Q000502:physiology; D047388:Casein Kinases; D002453:Cell Cycle; D003513:Cycloheximide / Q000494:pharmacology; D000518:Eflornithine / Q000494:pharmacology; D004790:Enzyme Induction; D005260:Female; D015759:Ionomycin / Q000494:pharmacology; D008213:Lymphocyte Activation; D008211:Lymphocyte Cooperation; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D065108:Ornithine Decarboxylase Inhibitors; D011073:Polyamines / Q000494:pharmacology; D011493:Protein Kinase C / Q000502:physiology; D011494:Protein Kinases / Q000378:metabolism*; D006377:T-Lymphocytes, Helper-Inducer / Q000502:physiology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
chemical_list: D065108:Ornithine Decarboxylase Inhibitors; D011073:Polyamines; D015759:Ionomycin; D003994:Bucladesine; D003513:Cycloheximide; D011494:Protein Kinases; D047388:Casein Kinases; D011493:Protein Kinase C; D013755:Tetradecanoylphorbol Acetate; D002118:Calcium; D000518:Eflornithine